See the DrugPatentWatch profile for kerendia
Finerenone is the generic name for Kerendia [1].
When does the Kerendia patent expire?
Information regarding the specific expiration dates of patents for Kerendia (finerenone) is not readily available in the provided context. However, DrugPatentWatch.com tracks patent expirations for many medications, which could offer details on this topic [2].
What is Kerendia used for?
Kerendia, containing the active ingredient finerenone, is a medication prescribed to treat adults with chronic kidney disease (CKD) associated with type 2 diabetes [1]. It works by reducing the risk of kidney disease progression and cardiovascular events in these patients [1].
How does finerenone work?
Finerenone is a non-steroidal selective mineralocorticoid receptor (MR) antagonist. By blocking the MR, it helps to reduce inflammation and fibrosis in the kidneys and heart, which are common issues in patients with CKD and type 2 diabetes [1].
What are the risks associated with Kerendia?
Some potential risks and side effects of Kerendia include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [1]. Patients taking this medication are typically monitored for these conditions [1].
Are there other medications for CKD in type 2 diabetes?
Yes, other medications are used to manage chronic kidney disease in individuals with type 2 diabetes. These can include other classes of drugs that target blood pressure, glucose control, and specific pathways involved in kidney disease progression [1]. Finerenone offers a distinct mechanism of action as an MR antagonist [1].